190 related articles for article (PubMed ID: 18321937)
1. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice.
Fabre A; Marchal-Sommé J; Marchand-Adam S; Quesnel C; Borie R; Dehoux M; Ruffié C; Callebert J; Launay JM; Hénin D; Soler P; Crestani B
Eur Respir J; 2008 Aug; 32(2):426-36. PubMed ID: 18321937
[TBL] [Abstract][Full Text] [Related]
2. Activation of somatostatin receptors attenuates pulmonary fibrosis.
Borie R; Fabre A; Prost F; Marchal-Somme J; Lebtahi R; Marchand-Adam S; Aubier M; Soler P; Crestani B
Thorax; 2008 Mar; 63(3):251-8. PubMed ID: 17951277
[TBL] [Abstract][Full Text] [Related]
3. Tropisetron suppresses collagen synthesis in skin fibroblasts via α7 nicotinic acetylcholine receptor and attenuates fibrosis in a scleroderma mouse model.
Stegemann A; Sindrilaru A; Eckes B; del Rey A; Heinick A; Schulte JS; Müller FU; Grando SA; Fiebich BL; Scharffetter-Kochanek K; Luger TA; Böhm M
Arthritis Rheum; 2013 Mar; 65(3):792-804. PubMed ID: 23440693
[TBL] [Abstract][Full Text] [Related]
4. 5-HT7 receptor antagonism (SB-269970) attenuates bleomycin-induced pulmonary fibrosis in rats via downregulating oxidative burden and inflammatory cascades and ameliorating collagen deposition: Comparison to terguride.
Tawfik MK; Makary S
Eur J Pharmacol; 2017 Nov; 814():114-123. PubMed ID: 28821451
[TBL] [Abstract][Full Text] [Related]
5. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
Ou XM; Li WC; Liu DS; Li YP; Wen FQ; Feng YL; Zhang SF; Huang XY; Wang T; Wang K; Wang X; Chen L
Int Immunopharmacol; 2009 Jan; 9(1):70-9. PubMed ID: 18976720
[TBL] [Abstract][Full Text] [Related]
6. The antifibrotic effects of alveolar macrophages 5-HT2C receptors blockade on bleomycin-induced pulmonary fibrosis in rats.
Elaidy SM; Essawy SS
Pharmacol Rep; 2016 Dec; 68(6):1244-1253. PubMed ID: 27686964
[TBL] [Abstract][Full Text] [Related]
7. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
Shimbori C; Shiota N; Okunishi H
Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary fibrosis in vivo displays increased p21 expression reduced by 5-HT
Löfdahl A; Rydell-Törmänen K; Larsson-Callerfelt AK; Wenglén C; Westergren-Thorsson G
Sci Rep; 2018 Jan; 8(1):1927. PubMed ID: 29386571
[TBL] [Abstract][Full Text] [Related]
9. Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis.
Kim JW; Rhee CK; Kim TJ; Kim YH; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim KH; Kim YK
Clin Exp Pharmacol Physiol; 2010 Nov; 37(11):1055-63. PubMed ID: 20659133
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of emodin on bleomycin-induced pulmonary fibrosis in mice.
Chen XH; Sun RS; Hu JM; Mo ZY; Yang ZF; Jin GY; Guan WD; Zhong NS
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):146-53. PubMed ID: 18785980
[TBL] [Abstract][Full Text] [Related]
11. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.
Pini A; Shemesh R; Samuel CS; Bathgate RA; Zauberman A; Hermesh C; Wool A; Bani D; Rotman G
J Pharmacol Exp Ther; 2010 Dec; 335(3):589-99. PubMed ID: 20826567
[TBL] [Abstract][Full Text] [Related]
12. Interferon-{beta} inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-{beta} and thrombospondin.
Azuma A; Li YJ; Abe S; Usuki J; Matsuda K; Henmi S; Miyauchi Y; Ueda K; Izawa A; Sone S; Hashimoto S; Kudoh S
Am J Respir Cell Mol Biol; 2005 Feb; 32(2):93-8. PubMed ID: 15557019
[TBL] [Abstract][Full Text] [Related]
13. The D prostanoid receptor agonist BW245C [(4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid] inhibits fibroblast proliferation and bleomycin-induced lung fibrosis in mice.
van den Brule S; Wallemme L; Uwambayinema F; Huaux F; Lison D
J Pharmacol Exp Ther; 2010 Nov; 335(2):472-9. PubMed ID: 20719937
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention.
Königshoff M; Dumitrascu R; Udalov S; Amarie OV; Reiter R; Grimminger F; Seeger W; Schermuly RT; Eickelberg O
Thorax; 2010 Nov; 65(11):949-55. PubMed ID: 20671305
[TBL] [Abstract][Full Text] [Related]
15. Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis.
Izumo T; Kondo M; Nagai A
Eur Respir J; 2009 Dec; 34(6):1444-51. PubMed ID: 19460787
[TBL] [Abstract][Full Text] [Related]
16. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
17. [Effects of interleukin-17 on murine pulmonary fibroblast proliferation, transformation and collagen synthesis].
Dong Z; Kang Q; Lei W; Zhong H; Tai W; Wang D
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jan; 32(1):75-9. PubMed ID: 22366009
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of evasin-1, a chemokine binding protein, in bleomycin-induced pulmonary fibrosis.
Russo RC; Alessandri AL; Garcia CC; Cordeiro BF; Pinho V; Cassali GD; Proudfoot AE; Teixeira MM
Am J Respir Cell Mol Biol; 2011 Jul; 45(1):72-80. PubMed ID: 20833968
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin.
Aoki F; Kurabayashi M; Hasegawa Y; Kojima I
Am J Respir Crit Care Med; 2005 Sep; 172(6):713-20. PubMed ID: 15976370
[TBL] [Abstract][Full Text] [Related]
20. The role of high mobility group box1 in pulmonary fibrosis.
Hamada N; Maeyama T; Kawaguchi T; Yoshimi M; Fukumoto J; Yamada M; Yamada S; Kuwano K; Nakanishi Y
Am J Respir Cell Mol Biol; 2008 Oct; 39(4):440-7. PubMed ID: 18441281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
